June 9, 2023 – A wireless device called the UroMonitor enables accurate, noninvasive monitoring of bladder pressure in patients with overactive bladder, reports a pilot study in the July issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
“The UroMonitor is the first device to enable catheter-free telemetric ambulatory bladder pressure monitoring in humans,” comments senior author Margot S. Damaser, PhD, of Cleveland Clinic. “With further evaluation, the UroMonitor may provide a safe and reliable way to identify bladder events under more natural conditions, compared to standard testing in the urodynamic lab.”
New technology for continuous, catheter-free bladder pressure monitoring
Patients with incontinence and other urinary problems routinely undergo urodynamic testing to assess functioning of the lower urinary tract. However, these tests have important limitations – including the need for catheter placement and instillation of fluid into the bladder, which can be uncomfortable for the patient and may not reflect normal daily functioning.
The UroMonitor was developed as a noninvasive approach for assessing function of the lower urinary tract, without the need for catheter placement. The UroMonitor is a small, flexible device – no more than two inches across – that is placed into the patient’s bladder. Once in place, the device wirelessly transmits bladder pressure data to a small radio receiver taped to the lower abdomen.
In a pilot study to evaluate clinical safety and accuracy, Dr. Damaser and colleagues tested the UroMonitor in 11 women (median age 67 years) with symptoms of overactive bladder. After the patients underwent initial urodynamic testing, the UroMonitor device was inserted into the bladder via the urethra. Urodynamic testing was then repeated, with simultaneous transmission of bladder pressure data.
After catheter removal, the UroMonitor provided further bladder pressure measurements as the patients ambulated (average time 60 minutes) and eventually urinated, after which the device was easily removed. Patient comfort and pain scores were monitored throughout the study and at two days’ follow-up.
With further study, UroMonitor may avoid invasive urodynamic testing in some patients
The UroMonitor device was quickly and easily placed: median insertion time 17.5 seconds. There were no changes in urodynamic measurements made before versus after device placement. One patient had signs of bladder muscle spasms (detrusor overactivity) after UroMonitor placement. However, detrusor overactivity was much more frequent during urodynamic testing, possibly due to catheter-related irritation of the bladder.
Clinically relevant changes in bladder pressure detected by the UroMonitor aligned well with those measured on urodynamic testing. Ninety-eight percent of bladder pressure events detected by urodynamic testing were accurately detected by the UroMonitor. A few events were missed due to radio interference – a technical issue that was corrected later in the study.
Average differences in simultaneous urodynamic and UroMonitor measurements were small. Patients reported little or no pain during most phases of the study, and there were no adverse effects or complications related to the device.
The UroMonitor provides “a safe and clinically feasible approach for telemetric ambulatory urodynamic monitoring,” the preliminary study suggests. The device seems to perform “exceedingly well” in identifying clinically significant bladder pressure events that could otherwise be captured only by standard urodynamic studies with catheter placement.
While further studies are needed, the UroMonitor may “more accurately reproduce bladder function” in patients with lower urinary tract symptoms. Using this along with other noninvasive methods, “[U]rologists may be able to more adequately capture a patient’s true voiding behaviors and defer invasive urodynamic studies in select patients,” Dr. Damaser and coauthors conclude.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
###
About The Journal of Urology®
The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.
About the American Urological Association
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
